{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,19]],"date-time":"2026-11-19T16:51:38Z","timestamp":1795107098569,"version":"4.10.3"},"reference-count":46,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2023,4,17]],"date-time":"2023-04-17T00:00:00Z","timestamp":1681689600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2023,4,17]],"date-time":"2023-04-17T00:00:00Z","timestamp":1681689600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100001691","name":"Japan Society for the Promotion of Science","doi-asserted-by":"crossref","award":["20K07168"],"award-info":[{"award-number":["20K07168"]}],"id":[{"id":"10.13039\/501100001691","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cancer Cell Int"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>KRAS mutations are fraught with the progression of colorectal cancer and resistance to chemotherapy. There are pathways such as extracellular regulated protein kinase 1\/2 (ERK1\/2) and Akt downstream and farnesylation and geranylgeranylation upstream that are activated upon mutated KRAS. Previous studies have shown that statins, 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors, are effective to treat KRAS mutated colorectal cancer cells. Increased doses of oxaliplatin (L-OHP), a well-known alkylating chemotherapeutic drug, causes side effects such as peripheral neuropathy due to ERK1\/2 activation in spinal cords. Hence, we examined the combinatorial therapeutic efficacy of statins and L-OHP to reduce colorectal cancer cell growth and abrogate neuropathy in mice.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>Cell survival and confirmed apoptosis was assessed using WST-8 assay and Annexin V detection kit. Detection of phosphorylated and total proteins was analyzed the western blotting. Combined effect of simvastatin and L-OHP was examined the allograft mouse model and L-OHP-induced neuropathy was assessed using cold plate and von Frey filament test.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      In this study, we examined the effect of combining statins with L-OHP on induction of cell death in colorectal cancer cell lines and improvement of L-OHP-induced neuropathy in vivo\n                      <jats:italic>.<\/jats:italic>\n                      We demonstrated that combined administration with statins and L-OHP significantly induced apoptosis and elevated the sensitivity of KRAS-mutated colorectal cancer cells to L-OHP. In addition, simvastatin suppressed KRAS prenylation, thereby enhancing antitumor effect of L-OHP through downregulation of survivin, XIAP, Bcl-xL, and Bcl-2, and upregulation of p53 and PUMA via inhibition of nuclear factor of \u03baB (NF-\u03baB) and Akt activation, and induction of c-Jun N-terminal kinase (JNK) activation in KRAS-mutated colorectal cancer cells. Moreover, simvastatin enhanced the antitumor effects of L-OHP and suppressed L-OHP-induced neuropathy via ERK1\/2 activation in\n                      <jats:italic>vivo<\/jats:italic>\n                      .\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Therefore, statins may be therapeutically useful as adjuvants to L-OHP in KRAS-mutated colorectal cancer and may also be useful in the treatment of L-OHP-induced neuropathy.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s12935-023-02884-z","type":"journal-article","created":{"date-parts":[[2023,4,17]],"date-time":"2023-04-17T04:02:45Z","timestamp":1681704165000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":22,"title":["Statins enhances antitumor effect of oxaliplatin in KRAS-mutated colorectal cancer cells and inhibits oxaliplatin-induced neuropathy"],"prefix":"10.1186","volume":"23","author":[{"given":"Masanobu","family":"Tsubaki","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tomoya","family":"Takeda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takuya","family":"Matsuda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kana","family":"Kishimoto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Honoka","family":"Takefuji","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuzuki","family":"Taniwaki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Misa","family":"Ueda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tadafumi","family":"Hoshida","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kazufumi","family":"Tanabe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shozo","family":"Nishida","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,4,17]]},"reference":[{"issue":"4","key":"2884_CR1","doi-asserted-by":"publisher","first-page":"e0174848","DOI":"10.1371\/journal.pone.0174848","volume":"12","author":"A Nanri","year":"2017","unstructured":"Nanri A, Mizoue T, Shimazu T, Ishihara J, Takachi R, Noda M, Iso H, Sasazuki S, Sawada N, Tsugane S, Japan Public Health Center-Based Prospective Study Group. Dietary patterns and all-cause, cancer, and cardiovascular disease mortality in Japanese men and women: The Japan public health center-based prospective study. PLoS ONE. 2017;12(4):e0174848.","journal-title":"PLoS ONE."},{"issue":"2","key":"2884_CR2","doi-asserted-by":"publisher","first-page":"68","DOI":"10.1097\/COC.0000000000000785","volume":"44","author":"EI Marks","year":"2021","unstructured":"Marks EI, Matera R, Olszewski AJ, Yakirevich E, El-Deiry WS, Safran H, Carneiro BA. Mutations in DNA repair genes and clinical outcomes of patients with metastatic colorectal cancer receiving Oxaliplatin or Irinotecan-containing Regimens. Am J Clin Oncol. 2021;44(2):68\u201373.","journal-title":"Am J Clin Oncol"},{"issue":"5","key":"2884_CR3","doi-asserted-by":"publisher","first-page":"663","DOI":"10.1200\/JCO.2008.20.8397","volume":"27","author":"C Bokemeyer","year":"2009","unstructured":"Bokemeyer C, Bondarenko I, Makhson A, Hartmann JT, Aparicio J, de Braud F, Donea S, Ludwig H, Schuch G, Stroh C, Loos AH, Zubel A, Koralewski P. Fluorouracil, leucovorin, and oxaliplatin with and without cetuximab in the first-line treatment of metastatic colorectal cancer. J Clin Oncol. 2009;27(5):663\u201371.","journal-title":"J Clin Oncol"},{"issue":"Suppl 2","key":"2884_CR4","doi-asserted-by":"publisher","first-page":"S96","DOI":"10.21037\/atm.2018.11.22","volume":"6","author":"R Ehrenberg","year":"2018","unstructured":"Ehrenberg R, Halama N. FOLFOX plus cetuximab in first-line therapy of advanced colorectal cancer. Ann Transl Med. 2018;6(Suppl 2):S96.","journal-title":"Ann Transl Med"},{"issue":"15","key":"2884_CR5","doi-asserted-by":"publisher","first-page":"4384","DOI":"10.1021\/bi027227m","volume":"42","author":"SA Holstein","year":"2003","unstructured":"Holstein SA, Wohlford-Lenane CL, Wiemer DF, Hohl RJ. Isoprenoid pyrophosphate analogues regulate expression of Ras-related proteins. Biochemistry. 2003;42(15):4384\u201391.","journal-title":"Biochemistry"},{"issue":"3","key":"2884_CR6","doi-asserted-by":"publisher","first-page":"549","DOI":"10.1016\/j.ygyno.2010.08.017","volume":"119","author":"B Taylor-Harding","year":"2010","unstructured":"Taylor-Harding B, Orsulic S, Karlan BY, Li AJ. Fluvastatin and cisplatin demonstrate synergistic cytotoxicity in epithelial ovarian cancer cells. Gynecol Oncol. 2010;119(3):549\u201356.","journal-title":"Gynecol Oncol"},{"issue":"12","key":"2884_CR7","doi-asserted-by":"publisher","first-page":"2844","DOI":"10.1111\/bph.15420","volume":"179","author":"FM Healy","year":"2022","unstructured":"Healy FM, Prior IA, MacEwan DJ. The importance of Ras in drug resistance in cancer. Br J Pharmacol. 2022;179(12):2844\u201367.","journal-title":"Br J Pharmacol"},{"issue":"9","key":"2884_CR8","doi-asserted-by":"publisher","first-page":"2201","DOI":"10.3390\/cancers13092201","volume":"13","author":"H Bellio","year":"2021","unstructured":"Bellio H, Fumet JD, Ghiringhelli F. Targeting BRAF and RAS in colorectal cancer. Cancers. 2021;13(9):2201.","journal-title":"Cancers"},{"key":"2884_CR9","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1016\/j.biopha.2015.12.017","volume":"78","author":"M Tsubaki","year":"2016","unstructured":"Tsubaki M, Mashimo K, Takeda T, Kino T, Fujita A, Itoh T, Imano M, Sakaguchi K, Satou T, Nishida S. Statins inhibited the MIP-1\u03b1 expression via inhibition of Ras\/ERK and Ras\/Akt pathways in myeloma cells. Biomed Pharmacother. 2016;78:23\u20139.","journal-title":"Biomed Pharmacother"},{"issue":"2","key":"2884_CR10","doi-asserted-by":"publisher","first-page":"222","DOI":"10.1111\/1440-1681.12690","volume":"44","author":"M Tsubaki","year":"2017","unstructured":"Tsubaki M, Fujiwara D, Takeda T, Kino T, Tomonari Y, Itoh T, Imano M, Satou T, Sakaguchi K, Nishida S. The sensitivity of head and neck carcinoma cells to statins is related to the expression of their Ras expression status, and statin-induced apoptosis is mediated via suppression of the Ras\/ERK and Ras\/mTOR pathways. Clin Exp Pharmacol Physiol. 2017;44(2):222\u201334.","journal-title":"Clin Exp Pharmacol Physiol"},{"issue":"1","key":"2884_CR11","doi-asserted-by":"publisher","first-page":"74","DOI":"10.1186\/1756-9966-30-74","volume":"30","author":"M Yanae","year":"2011","unstructured":"Yanae M, Tsubaki M, Satou T, Itoh T, Imano M, Yamazoe Y, Nishida S. Statin-induced apoptosis via the suppression of ERK1\/2 and Akt activation by inhibition of the geranylgeranyl-pyrophosphate biosynthesis in glioblastoma. J Exp Clin Cancer Res. 2011;30(1):74.","journal-title":"J Exp Clin Cancer Res"},{"issue":"8","key":"2884_CR12","first-page":"2223","volume":"5","author":"B Agarwal","year":"1999","unstructured":"Agarwal B, Bhendwal S, Halmos B, Moss SF, Ramey WG, Holt PR. Lovastatin augments apoptosis induced by chemotherapeutic agents in colon cancer cells. Clin Cancer Res. 1999;5(8):2223\u20139.","journal-title":"Clin Cancer Res"},{"issue":"4","key":"2884_CR13","doi-asserted-by":"publisher","first-page":"482","DOI":"10.1038\/onc.2009.356","volume":"29","author":"A Tesniere","year":"2010","unstructured":"Tesniere A, Schlemmer F, Boige V, Kepp O, Martins I, Ghiringhelli F, Aymeric L, Michaud M, Apetoh L, Barault L, Mendiboure J, Pignon JP, Jooste V, van Endert P, Ducreux M, Zitvogel L, Piard F, Kroemer G. Immunogenic death of colon cancer cells treated with oxaliplatin. Oncogene. 2010;29(4):482\u201391.","journal-title":"Oncogene"},{"key":"2884_CR14","doi-asserted-by":"publisher","DOI":"10.3389\/fmolb.2021.643824","volume":"8","author":"JJV Branca","year":"2021","unstructured":"Branca JJV, Carrino D, Gulisano M, Ghelardini C, Di Cesare ML, Pacini A. Oxaliplatin-induced neuropathy: genetic and epigenetic profile to better understand how to Ameliorate this side effect. Front Mol Biosci. 2021;8: 643824.","journal-title":"Front Mol Biosci"},{"issue":"1","key":"2884_CR15","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1016\/S0014-2999(00)00667-1","volume":"406","author":"H Adelsberger","year":"2000","unstructured":"Adelsberger H, Quasthoff S, Grosskreutz J, Lepier A, Eckel F, Lersch C. The chemotherapeutic oxaliplatin alters voltage-gated Na(+) channel kinetics on rat sensory neurons. Eur J Pharmacol. 2000;406(1):25\u201332.","journal-title":"Eur J Pharmacol"},{"issue":"5 Suppl 15","key":"2884_CR16","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1053\/sonc.2002.35525","volume":"29","author":"E Gamelin","year":"2002","unstructured":"Gamelin E, Gamelin L, Bossi L, Quasthoff S. Clinical aspects and molecular basis of oxaliplatin neurotoxicity: current management and development of preventive measures. Semin Oncol. 2002;29(5 Suppl 15):21\u201333.","journal-title":"Semin Oncol"},{"issue":"1","key":"2884_CR17","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1002\/mus.20340","volume":"32","author":"AV Krishnan","year":"2005","unstructured":"Krishnan AV, Goldstein D, Friedlander M, Kiernan MC. Oxaliplatin-induced neurotoxicity and the development of neuropathy. Muscle Nerve. 2005;32(1):51\u201360.","journal-title":"Muscle Nerve"},{"issue":"1","key":"2884_CR18","doi-asserted-by":"publisher","first-page":"243","DOI":"10.1002\/ijc.29367","volume":"137","author":"M Tsubaki","year":"2015","unstructured":"Tsubaki M, Takeda T, Tani T, Shimaoka H, Suzuyama N, Sakamoto K, Fujita A, Ogawa N, Itoh T, Imano M, Funakami Y, Ichida S, Satou T, Nishida S. PKC\/MEK inhibitors suppress oxaliplatin-induced neuropathy and potentiate the antitumor effects. Int J Cancer. 2015;137(1):243\u201350.","journal-title":"Int J Cancer"},{"key":"2884_CR19","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejphar.2021.173957","volume":"898","author":"Y Morii","year":"2021","unstructured":"Morii Y, Tsubaki M, Takeda T, Otubo R, Seki S, Yamatomo Y, Imano M, Satou T, Shimomura K, Nishida S. Perifosine enhances the potential antitumor effect of 5-fluorouracil and oxaliplatin in colon cancer cells harboring the PIK3CA mutation. Eur J Pharmacol. 2021;898: 173957.","journal-title":"Eur J Pharmacol"},{"key":"2884_CR20","doi-asserted-by":"publisher","first-page":"155591","DOI":"10.1016\/j.cyto.2021.155591","volume":"144","author":"M Tsubaki","year":"2021","unstructured":"Tsubaki M, Takeda T, Matsuda T, Yamamoto Y, Higashinaka A, Yamamoto K, Tsurushima K, Ishizaka T, Nishida S. Interleukin 19 suppresses RANKL-induced osteoclastogenesis via the inhibition of NF-\u03baB and p38MAPK activation and c-Fos expression in RAW2647 cells. Cytokine. 2021;144:155591.","journal-title":"Cytokine"},{"issue":"7","key":"2884_CR21","first-page":"1239","volume":"8","author":"M Tsubaki","year":"2018","unstructured":"Tsubaki M, Takeda T, Matsumoto M, Kato N, Asano RT, Imano M, Satou T, Nishida S. Trametinib suppresses chemotherapy-induced cold and mechanical allodynia via inhibition of extracellular-regulated protein kinase 1\/2 activation. Am J Cancer Res. 2018;8(7):1239\u201348.","journal-title":"Am J Cancer Res"},{"issue":"10","key":"2884_CR22","doi-asserted-by":"publisher","first-page":"101042831880867","DOI":"10.1177\/1010428318808670","volume":"40","author":"M Tsubaki","year":"2018","unstructured":"Tsubaki M, Takeda T, Matsumoto M, Kato N, Yasuhara S, Koumoto YI, Imano M, Satou T, Nishida S. Tamoxifen suppresses paclitaxel-, vincristine-, and bortezomib-induced neuropathy via inhibition of the protein kinase C\/extracellular signal-regulated kinase pathway. Tumour Biol. 2018;40(10):1010428318808670.","journal-title":"Tumour Biol"},{"issue":"1\u20132","key":"2884_CR23","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1016\/S0304-3959(00)00240-2","volume":"86","author":"I Takasaki","year":"2000","unstructured":"Takasaki I, Andoh T, Shiraki K, Kuraishi Y. Allodynia and hyperalgesia induced by herpes simplex virus type-1 infection in mice. Pain. 2000;86(1\u20132):95\u2013101.","journal-title":"Pain"},{"issue":"5","key":"2884_CR24","doi-asserted-by":"publisher","first-page":"266","DOI":"10.1002\/emmm.201100134","volume":"3","author":"J Descoeur","year":"2011","unstructured":"Descoeur J, Pereira V, Pizzoccaro A, Francois A, Ling B, Maffre V, Couette B, Busserolles J, Courteix C, Noel J, Lazdunski M, Eschalier A, Authier N, Bourinet E. Oxaliplatin-induced cold hypersensitivity is due to remodelling of ion channel expression in nociceptors. EMBO Mol Med. 2011;3(5):266\u201378.","journal-title":"EMBO Mol Med"},{"issue":"3","key":"2884_CR25","doi-asserted-by":"publisher","first-page":"428","DOI":"10.2174\/1871520617666171026170009","volume":"18","author":"MP Singh","year":"2018","unstructured":"Singh MP, Park KH, Khaket TP, Kang SC. CJK-7, a Novel Flavonoid from Paulownia tomentosa Triggers Cell Death Cascades in HCT-116 Human Colon Carcinoma Cells via Redox Signaling. Anticancer Agents Med Chem. 2018;18(3):428\u201337.","journal-title":"Anticancer Agents Med Chem"},{"issue":"5","key":"2884_CR26","doi-asserted-by":"publisher","first-page":"643","DOI":"10.1001\/jamaoncol.2015.5225","volume":"2","author":"J Taieb","year":"2016","unstructured":"Taieb J, Zaanan A, Le Malicot K, Juli\u00e9 C, Blons H, Mineur L, Bennouna J, Tabernero J, Mini E, Folprecht G, Van Laethem JL, Lepage C, Emile JF, Laurent-Puig P. Prognostic effect of BRAF and KRAS mutations in patients with stage III Colon Cancer Treated With Leucovorin, Fluorouracil, and Oxaliplatin With or Without Cetuximab: A Post Hoc Analysis of the PETACC-8 Trial. JAMA Oncol. 2016;2(5):643\u201353.","journal-title":"JAMA Oncol"},{"issue":"8","key":"2884_CR27","doi-asserted-by":"publisher","first-page":"674","DOI":"10.1093\/jnci\/djr070","volume":"103","author":"J Lee","year":"2011","unstructured":"Lee J, Lee I, Han B, Park JO, Jang J, Park C, Kang WK. Effect of simvastatin on cetuximab resistance in human colorectal cancer with KRAS mutations. J Natl Cancer Inst. 2011;103(8):674\u201388.","journal-title":"J Natl Cancer Inst"},{"issue":"2","key":"2884_CR28","doi-asserted-by":"publisher","first-page":"470","DOI":"10.1053\/j.gastro.2017.05.011","volume":"153","author":"PW Voorneveld","year":"2017","unstructured":"Voorneveld PW, Reimers MS, Bastiaannet E, Jacobs RJ, van Eijk R, Zanders MMJ, Herings RMC, van Herk-Sukel MPP, Kodach LL, van Wezel T, Kuppen PJK, Morreau H, van de Velde CJH, Hardwick JCH, Liefers GJ. Statin use after diagnosis of colon cancer and patient survival. Gastroenterology. 2017;153(2):470-479.e4.","journal-title":"Gastroenterology"},{"issue":"1","key":"2884_CR29","doi-asserted-by":"publisher","first-page":"128","DOI":"10.1186\/s12943-021-01422-7","volume":"20","author":"D Tang","year":"2021","unstructured":"Tang D, Kroemer G, Kang R. Oncogenic KRAS blockade therapy: renewed enthusiasm and persistent challenges. Mol Cancer. 2021;20(1):128.","journal-title":"Mol Cancer"},{"issue":"10","key":"2884_CR30","doi-asserted-by":"publisher","first-page":"101042831773494","DOI":"10.1177\/1010428317734947","volume":"39","author":"D Fujiwara","year":"2017","unstructured":"Fujiwara D, Tsubaki M, Takeda T, Tomonari Y, Koumoto YI, Sakaguchi K, Nishida S. Statins induce apoptosis through inhibition of Ras signaling pathways and enhancement of Bim and p27 expression in human hematopoietic tumor cells. Tumour Biol. 2017;39(10):1010428317734947.","journal-title":"Tumour Biol"},{"issue":"6","key":"2884_CR31","doi-asserted-by":"publisher","first-page":"481","DOI":"10.3892\/ol.2021.12742","volume":"21","author":"X Zhu","year":"2021","unstructured":"Zhu X, Luo X, Song Z, Jiang S, Long X, Gao X, Xie X, Zheng L, Wang H. miR-188-5p promotes oxaliplatin resistance by targeting RASA1 in colon cancer cells. Oncol Lett. 2021;21(6):481.","journal-title":"Oncol Lett"},{"issue":"4","key":"2884_CR32","doi-asserted-by":"publisher","first-page":"951","DOI":"10.1002\/ijc.23593","volume":"123","author":"SJ Cho","year":"2008","unstructured":"Cho SJ, Kim JS, Kim JM, Lee JY, Jung HC, Song IS. Simvastatin induces apoptosis in human colon cancer cells and in tumor xenografts, and attenuates colitis-associated colon cancer in mice. Int J Cancer. 2008;123(4):951\u20137.","journal-title":"Int J Cancer"},{"issue":"1","key":"2884_CR33","doi-asserted-by":"publisher","first-page":"128","DOI":"10.1345\/aph.1E319","volume":"39","author":"RJ Cersosimo","year":"2005","unstructured":"Cersosimo RJ. Oxaliplatin-associated neuropathy: a review. Ann Pharmacother. 2005;39(1):128\u201335.","journal-title":"Ann Pharmacother"},{"key":"2884_CR34","doi-asserted-by":"publisher","DOI":"10.3389\/fpain.2021.804260","volume":"2","author":"N Egashira","year":"2021","unstructured":"Egashira N. Pathological mechanisms and preventive strategies of Oxaliplatin-Induced Peripheral Neuropathy. Front Pain Res. 2021;2: 804260.","journal-title":"Front Pain Res"},{"issue":"11","key":"2884_CR35","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0225586","volume":"14","author":"T Maruta","year":"2019","unstructured":"Maruta T, Nemoto T, Hidaka K, Koshida T, Shirasaka T, Yanagita T, Takeya R, Tsuneyoshi I. Upregulation of ERK phosphorylation in rat dorsal root ganglion neurons contributes to oxaliplatin-induced chronic neuropathic pain. PLoS ONE. 2019;14(11): e0225586.","journal-title":"PLoS ONE"},{"issue":"4","key":"2884_CR36","doi-asserted-by":"publisher","first-page":"253","DOI":"10.1293\/tox.2016-0032","volume":"29","author":"H Chen","year":"2016","unstructured":"Chen H, Wang Q, Shi D, Yao D, Zhang L, Xiong J, Xu B. Celecoxib alleviates oxaliplatin-induced hyperalgesia through inhibition of spinal ERK1\/2 signaling. J Toxicol Pathol. 2016;29(4):253\u20139.","journal-title":"J Toxicol Pathol"},{"issue":"1","key":"2884_CR37","doi-asserted-by":"publisher","first-page":"30","DOI":"10.3390\/ph14010030","volume":"14","author":"N Kato","year":"2020","unstructured":"Kato N, Tateishi K, Tsubaki M, Takeda T, Matsumoto M, Tsurushima K, Ishizaka T, Nishida S. Gabapentin and Duloxetine Prevent Oxaliplatin- and Paclitaxel-Induced Peripheral Neuropathy by Inhibiting Extracellular Signal-Regulated Kinase 1\/2 (ERK1\/2) Phosphorylation in Spinal Cords of Mice. Pharmaceuticals (Basel). 2020;14(1):30.","journal-title":"Pharmaceuticals (Basel)"},{"issue":"12","key":"2884_CR38","doi-asserted-by":"publisher","first-page":"1059","DOI":"10.1080\/01616412.2019.1672391","volume":"41","author":"Y Qian","year":"2019","unstructured":"Qian Y, Wang Q, Jiao J, Wang G, Gu Z, Huang D, Wang Z. Intrathecal injection of dexmedetomidine ameliorates chronic neuropathic pain via the modulation of MPK3\/ERK1\/2 in a mouse model of chronic neuropathic pain. Neurol Res. 2019;41(12):1059\u201368.","journal-title":"Neurol Res"},{"issue":"5","key":"2884_CR39","doi-asserted-by":"publisher","first-page":"682","DOI":"10.3324\/haematol.11020","volume":"92","author":"B von Tresckow","year":"2007","unstructured":"von Tresckow B, von Strandmann EP, Sasse S, Tawadros S, Engert A, Hansen HP. Simvastatin-dependent apoptosis in Hodgkin\u2019s lymphoma cells and growth impairment of human Hodgkin\u2019s tumors in vivo. Haematologica. 2007;92(5):682\u20135.","journal-title":"Haematologica"},{"issue":"1","key":"2884_CR40","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1002\/hon.869","volume":"27","author":"TE Sondergaard","year":"2009","unstructured":"Sondergaard TE, Pedersen PT, Andersen TL, S\u00f8e K, Lund T, Ostergaard B, Garnero P, Delaisse JM, Plesner T. A phase II clinical trial does not show that high dose simvastatin has beneficial effect on markers of bone turnover in multiple myeloma. Hematol Oncol. 2009;27(1):17\u201322.","journal-title":"Hematol Oncol"},{"issue":"24","key":"2884_CR41","doi-asserted-by":"publisher","first-page":"8648","DOI":"10.1158\/1078-0432.CCR-04-1568","volume":"10","author":"A Horiguchi","year":"2004","unstructured":"Horiguchi A, Sumitomo M, Asakuma J, Asano T, Asano T, Hayakawa M. 3-hydroxy-3-methylglutaryl-coenzyme a reductase inhibitor, fluvastatin, as a novel agent for prophylaxis of renal cancer metastasis. Clin Cancer Res. 2004;10(24):8648\u201355.","journal-title":"Clin Cancer Res"},{"issue":"20","key":"2884_CR42","doi-asserted-by":"publisher","first-page":"1540","DOI":"10.1093\/jnci\/djr307","volume":"103","author":"K Ng","year":"2011","unstructured":"Ng K, Ogino S, Meyerhardt JA, Chan JA, Chan AT, Niedzwiecki D, Hollis D, Saltz LB, Mayer RJ, Benson AB 3rd, Schaefer PL, Whittom R, Hantel A, Goldberg RM, Bertagnolli MM, Venook AP, Fuchs CS. Relationship between statin use and colon cancer recurrence and survival: results from CALGB 89803. J Natl Cancer Inst. 2011;103(20):1540\u201351.","journal-title":"J Natl Cancer Inst"},{"issue":"11","key":"2884_CR43","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0112201","volume":"9","author":"LL Krens","year":"2014","unstructured":"Krens LL, Simkens LH, Baas JM, Koomen ER, Gelderblom H, Punt CJ, Guchelaar HJ. Statin use is not associated with improved progression free survival in cetuximab treated KRAS mutant metastatic colorectal cancer patients: results from the CAIRO2 study. PLoS ONE. 2014;9(11): e112201.","journal-title":"PLoS ONE"},{"issue":"4","key":"2884_CR44","doi-asserted-by":"publisher","first-page":"890","DOI":"10.1016\/j.surg.2021.08.002","volume":"171","author":"A Pourlotfi","year":"2022","unstructured":"Pourlotfi A, Ahl Hulme R, Forssten MP, Sjolin G, Bass GA, Cao Y, Matthiessen P, Mohseni S. Statin therapy and its association with long-term survival after colon cancer surgery. Surgery. 2022;171(4):890\u20136.","journal-title":"Surgery"},{"issue":"11","key":"2884_CR45","doi-asserted-by":"publisher","first-page":"1217","DOI":"10.1097\/DCR.0b013e3182a4b236","volume":"56","author":"AG Mace","year":"2013","unstructured":"Mace AG, Gantt GA, Skacel M, Pai R, Hammel JP, Kalady MF. Statin therapy is associated with improved pathologic response to neoadjuvant chemoradiation in rectal cancer. Dis Colon Rectum. 2013;56(11):1217\u201327.","journal-title":"Dis Colon Rectum"},{"key":"2884_CR46","first-page":"2280440","volume":"2021","author":"G Li","year":"2021","unstructured":"Li G, Liu J. Analysis of efficacy, safety, and prognostic factors of mFOLFOX6 Regimen Combined with Cetuximab and Simvastatin in the Treatment of K-RAS Mutant Colorectal Cancer. Evid Based Complement Alternat Med. 2021;2021:2280440.","journal-title":"Evid Based Complement Alternat Med"}],"container-title":["Cancer Cell International"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12935-023-02884-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12935-023-02884-z\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12935-023-02884-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,4,17]],"date-time":"2023-04-17T04:06:44Z","timestamp":1681704404000},"score":1,"resource":{"primary":{"URL":"https:\/\/cancerci.biomedcentral.com\/articles\/10.1186\/s12935-023-02884-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,4,17]]},"references-count":46,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2023,12]]}},"alternative-id":["2884"],"URL":"https:\/\/doi.org\/10.1186\/s12935-023-02884-z","relation":{},"ISSN":["1475-2867"],"issn-type":[{"value":"1475-2867","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,4,17]]},"assertion":[{"value":"15 November 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 March 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 April 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"All animal experiments were approved by the Animal Care and Use Committee of Kindai University (project identification code KAPS-2020-011, April 1, 2020).","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"73"}}